Home › Funds › Eversept Partners, LP › TVTX
Eversept Partners, LP position in TVTX
TRAVERE THERAPEUTICS INC · Health Care
Eversept Partners, LP reported holding 453,866 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$26.7M, representing 1.44% of its reported portfolio and ranking #19 among its reported holdings. Eversept Partners, LP has disclosed TVTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's TVTX position evolved
Eversept Partners, LP first disclosed a stake in TVTX in Q1 2024 at 955,618 shares (US$7.4M). The position peaked in Q2 2026 at 798,973 shares, worth US$45.4M. Across 11 filings, Eversept Partners, LP increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 453,866 shares valued at US$26.7M — a reduction of -345,107 shares quarter over quarter.. Notable position changes include a 66% increase in Q1 2025 (shares fell 17% over the following quarter), a 61% increase in Q2 2025 (shares rose 61% over the following quarter), a 54% trim in Q1 2026 (shares rose 91% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 955.62K | $7.37M | New |
| Q2 2024 | 1.09M | $8.97M | Add |
| Q3 2024 | 869.91K | $12.17M | Reduce |
| Q4 2024 | 490.30K | $8.54M | Reduce |
| Q1 2025 | 816.25K | $14.63M | Add |
| Q2 2025 | 1.32M | $19.46M | Add |
| Q3 2025 | 1.42M | $33.87M | Add |
| Q4 2025 | 1.17M | $44.90M | Reduce |
| Q1 2026 | 542.61K | $16.12M | Reduce |
| Q2 2026 | 798.97K | $45.39M | Add |
| Q3 2026 | 453.87K | $26.72M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TVTX and 13F data
TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$129.8M), Kynam Capital Management, LP (US$117.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TVTX
- PERCEPTIVE ADVISORS LLC 3.75M sh · $213.18M · Q2 2026
- Rock Springs Capital Management LP 2.20M sh · $129.78M · Q3 2026
- Kynam Capital Management, LP 2.00M sh · $117.76M · Q3 2026
- Stephens Investment Management Group LLC 1.88M sh · $110.50M · Q3 2026
- EMERALD ADVISERS, LLC 1.56M sh · $92.06M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.53M sh · $90.27M · Q3 2026
- Context Capital Management, LLC 62.70M sh · $73.14M · Q3 2026
- MPM BioImpact LLC 1.12M sh · $63.78M · Q2 2026
- EMERALD MUTUAL FUND ADVISERS TRUST 984.85K sh · $57.99M · Q3 2026
- Jones Hill Capital LP 959.63K sh · $56.50M · Q3 2026
- ARMISTICE CAPITAL, LLC 720.00K sh · $42.39M · Q3 2026
- Polar Asset Management Partners Inc. 30.50M sh · $35.91M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held TVTX?
Eversept Partners, LP has disclosed TVTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Eversept Partners, LP's current position in TVTX?
As of Q3 2026, Eversept Partners, LP holds 453.87K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $26.72M, representing 1.44% of its reported portfolio and ranking #19.
Has Eversept Partners, LP been buying or selling TVTX?
In the latest 13F filing (Q3 2026), Eversept Partners, LP reduced its position in TVTX. The position peaked in Q2 2026 at 798.97K shares.
Which other funds hold TVTX?
Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.